← All trials
NCT06905509
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2025
- Primary completion
- Jul 1, 2028
- Completion date
- Aug 1, 2030
- First posted
- Apr 1, 2025
- Last posted
- Sep 29, 2025
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, DavisLead sponsor
- National Cancer Institute (NCI)Collaborator
- University of California, DavisOfficial
- University of California, DavisSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.